Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CD26 is a lymphocyte marker that can anchor
adenosine deaminase
(
ADA
) on the T cell surface. We found that
ADA
is regulated by cytokines on the cell surface during T cell activation. By means of flow cytometry, immunofluorescence, and immunoblotting techniques, we found that interleukin (IL)-2 and IL-12 up-regulate ecto-
ADA
and CD26 expression. In clear contrast, IL-4 led to down-regulation of lymphocyte surface
ADA
without modifying the level of CD26. Moreover, neither circulating
ADA
transcription nor mRNA translation was regulated by cytokines. These results, along with absence of total-
ADA
modulation, the variable amount of
ADA
found in purified plasma membranes, and the different effect of
Brefeldin A
on the surface presence of
ADA
and CD26 indicated that cytokines regulate the translocation of
ADA
towards the cell surface through a mechanism not involving CD26. Ecto-
ADA
protected activated lymphocytes from the toxic effects of extracellular adenosine. Therefore, this cell surface
ADA
control might constitute part of the fine immunoregulatory mechanism of adenosine-mediated signaling through purinergic receptors in leukocytes.
...
PMID:Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. 1173 55
